BridgeBio Pharma, Inc. financial data

Symbol
BBIO on Nasdaq
Industry
Pharmaceutical Preparations
Location
3160 Porter Dr., Suite 250, Palo Alto, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
BridgeBio Pharma LLC (to 5/16/2019)
Latest financial report
10-K - Q4 2024 - Feb 20, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 450 % +0.29%
Debt-to-equity -166 % -14.9%
Operating Margin -267 % +95.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 190M shares
Common Stock, Shares, Outstanding 190M shares +8.55%
Common Stock, Value, Issued 196K USD +8.29%
Weighted Average Number of Shares Outstanding, Basic 186M shares +14.3%
Weighted Average Number of Shares Outstanding, Diluted 186M shares +14.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 222M USD +2285%
Cost of Revenue 3.88M USD +58.5%
Research and Development Expense 506M USD +11.1%
Costs and Expenses 815M USD +32.1%
Operating Income (Loss) -593M USD +2.37%
Nonoperating Income (Expense) 50.8M USD -667%
Income Tax Expense (Benefit) 1.15M USD
Earnings Per Share, Basic -2.88 USD/shares +27.1%
Earnings Per Share, Diluted -2.88 USD/shares +27.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 681M USD +81.2%
Accounts Receivable, after Allowance for Credit Loss, Current 4.72M USD +170%
Assets, Current 721M USD +50.9%
Property, Plant and Equipment, Net 7.01M USD -40.7%
Operating Lease, Right-of-Use Asset 5.77M USD -28.2%
Intangible Assets, Net (Excluding Goodwill) 23.9M USD -9.09%
Other Assets, Noncurrent 18.2M USD -19.6%
Assets 919M USD +68.3%
Accounts Payable, Current 9.62M USD -9.73%
Employee-related Liabilities, Current 58.3M USD +1.67%
Liabilities, Current 154M USD +7.34%
Operating Lease, Liability, Noncurrent 4.7M USD -47.7%
Other Liabilities, Noncurrent 286K USD -94.9%
Liabilities 2.38B USD +25.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 8K USD -74.2%
Retained Earnings (Accumulated Deficit) -3.1B USD -20.9%
Stockholders' Equity Attributable to Parent -1.47B USD -8.39%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -1.46B USD -8.54%
Liabilities and Equity 919M USD +68.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 196M shares +8.25%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 683M USD +73.1%
Deferred Tax Assets, Valuation Allowance 727M USD +8.22%
Deferred Tax Assets, Gross 729M USD +7.38%
Operating Lease, Liability 9.2M USD -29.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -536M USD +16.7%
Lessee, Operating Lease, Liability, to be Paid 10.1M USD -32.1%
Operating Lease, Liability, Current 4.51M USD +9.16%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.47M USD -37.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.93M USD +3.31%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 900K USD -49%
Lessee, Operating Lease, Liability, to be Paid, Year Three 436K USD -76.8%
Deferred Tax Assets, Operating Loss Carryforwards 379M USD +5.62%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 25M shares 0%
Unrecognized Tax Benefits 36.9M USD +19.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 439K USD -49%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 2.4M USD 0%
Deferred Tax Assets, Net of Valuation Allowance 1.31M USD -79.7%
Share-based Payment Arrangement, Expense 114M USD -1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%